Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia
| Autor: | Etsay Weldekidan Tsegay, Nigus Alemu Hailu, Zenawi Hagos Gufue, Desalegn Getnet Demise |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Agonist
medicine.drug_class business.industry Dopaminergic Glutamate receptor medicine.disease 030227 psychiatry 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Schizophrenia Dopamine medicine Serotonin Neurotransmitter business Receptor Neuroscience 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Neuropsychiatric Disease and Treatment. 16:2499-2509 |
| ISSN: | 1178-2021 |
| DOI: | 10.2147/ndt.s263424 |
| Popis: | Schizophrenia is a serious disease of the central nervous system that affects a person's ability to think, feel and behave clearly. Even though the pathophysiological hypothesis of the disease is not clearly understood, dysfunction of dopamine, glutamate, serotonin and other neurotransmitters is widely believed to be involved. Serotonin within the synaptic vesicles functions as neurotransmitter and neurohormone in regulation of emotion, learning, memory, hormone release, cognition and motor function. Dysfunction of normal brain activity of serotonin is associated with schizophrenia. The role of serotonin 6 and 7 receptors in schizophrenia, interaction with neurotransmitters and the effect of drugs on those receptors in schizophrenia are the goal of this review. The aim of this review was to provide information for researchers and other scholars to identify the possible intervention points in the management of schizophrenia. The serotonin 6 and 7 receptors are associated with schizophrenia via modulating cyclic adenosine monophosphate, regulation of Fyn kinase and induction of structural plasticity. The above modulatory effects affect cholinergic, dopaminergic, glutamatergic, adrenergic and GABAergic systems. Recently, diverse numbers of selective agonist and antagonist ligands were developed for both receptors. SGS-518, ABT-354, Lu AE58054, SB-742,457, S-518, AVN-211, AVN-322, SYN-114 and SYN-120 are serotonin 6 receptor antagonists and aripiprazole-controlled release serotonin 7 receptor agonists under clinical trial for schizophrenia. Thus, research on novel drugs that act on serotonin 6 and 7 receptors likely facilitates the intervention into schizophrenia patients seeking better quality of life in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|